Funxional Therapeutics Ltd.

Boehringer Ingelheim has acquired global rights to a Phase II respiratory compound and a broader inflammation development programme focused on a novel class of small molecule anti-inflammatory compoun

[Each week, “The Pink Sheet” presents commentary on some of the week’s most interesting business deals, contributed by the editors of the IN VIVO blog .] Every player in big pharma is facing a

IN VITRO DIAGNOSTICS Mergers & Acquisitions Life Technologies Corp. Navigenics Inc. In an initial move to build up its molecular diagnostics business, Life Technologies Corp. is buying privately h

XOMA, a company focused on the discovery and development of novel antibody therapeutics, has appointed Dr Paul Rubin vice-president and chief medical officer. Dr Rubin was previously CMO at Funxional